|Mr. Nadav Kidron Esq.||Chief Exec. Officer, Pres and Exec. Director||486.18k||N/A||43|
|Mrs. Yifat Zommer CPA||Chief Financial Officer, Treasurer and Sec.||177.25k||N/A||43|
|Mr. Joshua Hexter||Chief Operating Officer and VP of Bus. Devel.||N/A||N/A||47|
|Dr. Miriam Kidron Ph.D.||Chief Medical & Technology Officer, Chief Scientific Officer and Director||353.15k||N/A||77|
|Dr. Roy Eldor M.D., Ph.D.||Chief Medical Advisor and Member of the Scientific Advisory Board||N/A||N/A||N/A|
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes. The company operates primarily in Israel. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in Jerusalem, Israel.
Oramed Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.